Keros Therapeutics (KROS) Earnings Date & Reports

Key Takeaways

• Keros Therapeutics (KROS) is expected to report third-quarter 2026 results around November 4, 2026, with the conference call anticipated the following day.
• Wall Street consensus points to a loss of roughly $0.96 per share, narrowing from the $1.45 per-share loss reported in the prior quarter.
• Revenue estimates sit near $15 million, though a clinical-stage company with irregular collaboration income makes top-line figures highly variable.
• Investor attention is focused on rinvatercept, the company's lead candidate, and its Phase II study in Duchenne muscular dystrophy (DMD), a progressive muscle-wasting disorder.
• Keros held about $257.6 million in cash and cash equivalents at June 30, 2026, a runway management says extends into the first half of 2028.

Earnings Context and Why It Matters

Keros Therapeutics is a clinical-stage biopharmaceutical company developing treatments tied to the transforming growth factor-beta (TGF-β) family of proteins, which regulate cell growth and tissue repair. Because it has no marketed products, its income statement is driven less by recurring sales and more by collaboration revenue, research spending, and cash management. The upcoming quarterly report matters because it will show whether the company is controlling expenses while advancing rinvatercept through clinical development. With shares down roughly 45–50% year to date and revenue visibility limited, the Q3 update offers a key checkpoint on pipeline execution, cash runway, and the timing of future catalysts that could reshape the investment case.

Earnings Expectations

Consensus estimates for the third quarter of 2026 call for a loss of approximately $0.96 per share, a notable improvement from the $1.45 loss reported in the second quarter and the $1.21 loss in the first quarter. Revenue expectations land around $15 million, though these figures carry unusual uncertainty: Keros has no recurring product revenue and instead records service, collaboration, and license income as milestones are met.

Investors should keep this volatility in mind. In Q2 2026, Keros reported zero revenue, down from $18.2 million a year earlier, while research and development (R&D) expenses fell to $22.3 million after the transfer of elritercept-related costs to partner Takeda. For Q3, the key numbers to watch are the net loss, cash position, and any updated commentary on clinical timelines rather than the headline revenue figure alone.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following clinical-stage biotechnology names like KROS, tools that surface momentum and technical shifts can complement fundamental research on pipeline news and earnings events.

Market Reaction and Investor Sentiment

Sentiment heading into the Q3 report remains cautious. Keros shares have fallen significantly in 2026, reflecting a sharp drop in collaboration revenue following the 2025 Takeda licensing milestone and the market's growing focus on rinvatercept as the company's primary value driver. After the second-quarter report in August, the stock moved modestly, suggesting investors are weighing pipeline progress against a limited near-term revenue base. Analyst views are mixed: Wells Fargo initiated coverage with a Buy rating and an $18 price target in early August, while TD Cowen assigned a Hold rating the same day. With no recurring product sales, the earnings event is likely to be driven more by guidance on clinical milestones and cash runway than by the headline financial figures themselves.

Forward Outlook and Key Factors to Monitor

Following the Q3 release, investors should focus on clinical execution rather than quarterly revenue, given the absence of a marketed product. The most important catalyst is rinvatercept. Keros has initiated a Phase II study evaluating the candidate in Duchenne muscular dystrophy (DMD), following Phase I results that showed increases in muscle mass and bone mineral density alongside reduced fat mass. Initial data from the Phase II DMD study is expected in the first half of 2027.

Rinvatercept is also being developed for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. Keros has indicated plans to engage regulators on the design of a Phase II study in this indication, and any clarity on those discussions could be a meaningful signal for the pipeline's breadth.

On the financial side, watch the cash balance and spending trajectory. Cash and cash equivalents stood at $257.6 million as of June 30, 2026, and management expects current resources to fund operations into the first half of 2028. Meanwhile, elritercept, the company's most advanced candidate, remains in late-stage development for low blood-cell counts (cytopenias) under Takeda's exclusive worldwide rights outside mainland China, Hong Kong, and Macau. Any regulatory or clinical updates on that program could also move sentiment.

In short, the Q3 report is less about the numbers themselves and more about whether Keros can keep its pipeline on schedule while preserving a runway that carries it to the next wave of data readouts.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations